EQT Life Sciences leads USD 56 million Series D financing in Neuros Medical to commercialize FDA-approved treatment for post-amputation pain
- Proceeds will be used to support U.S. commercialization of Altius®, a direct electrical nerve stimulation system designed to treat chronic, intractable post-amputation pain in adult amputees
- Post-amputation pain is a severely underserved indication, affecting up to 80% of amputees in the U.S., with few effective non-opioid treatment options
EQT Life Sciences (“EQT”) is pleased to announce that the LSP 7 fund and the EQT Health Economics strategy have co-led the USD 56 million Series D financing round of Neuros Medical, Inc., a U.S.-based medical device company developing breakthrough treatments for chronic post-amputation pain. The oversubscribed round marks a significant milestone in supporting the company’s mission to address a critical unmet need.
Proceeds from the financing will be used to support U.S. commercialization of Altius®, a FDA-approved direct electrical nerve stimulation system designed to treat chronic, intractable post-amputation pain in adult amputees.
Post-amputation pain is a severely underserved indication, affecting up to 80 percent of amputees in the U.S., with few effective non-opioid treatment options. The Altius® system delivers targeted nerve stimulation through a patient-controlled, on-demand therapy, and is currently the only FDA-approved solution for post-amputation pain.
David Veino, President and CEO of Neuros Medical, commented: “This funding enables us to scale our commercial operations and expand access to a breakthrough non-opioid treatment for a highly underserved patient population. We are grateful for the support from EQT and our syndicate partners as we continue our mission to relieve pain and restore life for amputees."
Fouad Azzam, Ph.D., Partner in the EQT Life Sciences advisory team, commented: “Neuros Medical is addressing one of the most urgent and overlooked challenges in chronic pain management. EQT believes Altius has the potential to significantly improve the quality of life for amputees, and we are proud to partner with this team to bring the therapy to market.”
Contact
EQT Press Office, [email protected]
Downloads
About EQT
EQT is a purpose-driven global investment organization with EUR 273 billion in total assets under management (EUR 142 billion in fee-generating assets under management) as of 31 March 2025, within two business segments – Private Capital and Real Assets. EQT owns portfolio companies and assets in Europe, Asia Pacific and the Americas and supports them in achieving sustainable growth, operational excellence and market leadership.
More info: www.eqtgroup.com
Follow EQT on LinkedIn, X, YouTube and Instagram
About Neuros Medical
Founded to address the critical unmet need in chronic post-amputation pain, Neuros Medical is a privately held medical device company headquartered in Aliso Viejo, California. Its flagship product, the Altius® Direct Electrical Nerve Stimulation System, is a non-opioid, FDA-approved device that provides on-demand, patient-controlled pain relief by targeting peripheral nerves near the amputation site.
The system comprises a nerve cuff electrode and an implantable pulse generator, delivering 30-minute stimulation sessions as needed by the patient. With nearly 2 million amputees in the U.S. and 300,000 new amputations annually, the Altius® System offers a differentiated, scalable solution in a large and growing market.
For more information: www.neurosmedical.com
Exclusive News and Insights Every Week
Add your email address below to sign up for our EQT newsletters.